3 Research Driven Pharma Company, Specialty Chemicals Maker and Water Flow Control Products Maker Stocks With a Strong Future Roadmap: Glenmark Pharmaceuticals, Rossari Biotech and Jash Engineering

Pharma, specialty chemical and gate stocks bring together companies with a visible plan for the years ahead. Glenmark Pharmaceuticals, Rossari Biotech and Jash Engineering cover a research driven pharma company, a specialty chemicals maker and a water flow control products maker.

This list covers three pharma, specialty chemical and gate stocks with complete current figures: Glenmark Pharmaceuticals, Rossari Biotech and Jash Engineering. Every figure comes from the latest reported financials and the 3 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Pharma, Specialty Chemical and Gate Stocks?

Pharma, specialty chemical and gate stocks are listed companies that make branded generics and speciality medicines, produce home care, textile and animal nutrition chemicals, and build sluice gates, valves and penstocks for water and wastewater projects. Their earnings depend on prescriptions, chemical demand and water project spending.

Pharma, Specialty Chemical and Gate Stocks at a Glance

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing pharma, specialty chemical and gate stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Pharma, Specialty Chemical and Gate Stocks Have a Strong Roadmap in India?

Pharma, specialty chemical and gate stocks have a strong roadmap in India because growing medicine use, wider specialty chemical applications and large water infrastructure plans keep widening the market for these companies.

• Pharma. Branded and speciality medicines reach more patients.
• Specialty chemicals. Home and textile makers need performance ingredients.
• Flow control. Water projects need gates and valves.

Why Glenmark Pharmaceuticals Features Among These Pharma, Specialty Chemical and Gate Stocks

Among the pharma, specialty chemical and gate stocks on this list, Glenmark Pharmaceuticals is a research-driven pharma company with branded generics in India and other emerging markets, generics in the United States and Europe, and an innovation arm focused on new drugs.

The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7.

Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore.

Roadmap: The company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.

What to watch: Track new product launches, progress in the innovation pipeline and balance sheet strength.

Why Rossari Biotech Features Among These Pharma, Specialty Chemical and Gate Stocks

Among the pharma and flow control shares on this list, Rossari Biotech makes specialty chemicals for home, personal and performance applications, including textile chemicals, animal health and nutrition products and ingredients for fast-moving consumer goods.

Revenue rose from Rs 1,495 crore in FY22 to Rs 2,419 crore in FY26, a compound annual growth rate of 12.8%. Net profit grew from Rs 97.7 crore in FY22 to Rs 149 crore in FY26, which works out to a compound annual growth rate of 11.2%.

The company has a return on equity of 10.8%, a debt to equity ratio of 0.28 and a market capitalisation of Rs 2,363 crore. The stock trades at a P/E of 15.5, below the industry P/E of 33.9.

Roadmap: The company is broadening its range across home and personal care, animal nutrition and performance chemicals. Cross-selling to existing customers helps add volume.

What to watch: Track new product additions, customer wins and margin trends.

Why Jash Engineering Features Among These Pharma, Specialty Chemical and Gate Stocks

Among the three companies on this list, Jash Engineering makes flow control products such as sluice gates, valves, penstocks and screens for water and wastewater projects, and serves irrigation, power and industrial customers.

In the June 2026 quarter, revenue grew 17.3% year on year to Rs 156 crore. Revenue rose from Rs 374 crore in FY22 to Rs 757 crore in FY26, a compound annual growth rate of 19.3%.

Net profit grew from Rs 32.2 crore in FY22 to Rs 75.5 crore in FY26, which works out to a compound annual growth rate of 23.8%. The company has a return on equity of 14.7%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 3,380 crore. The stock trades at a P/E of 39.4, below the industry P/E of 44.4.

Roadmap: Spending on water supply, sewage treatment and irrigation projects creates a steady stream of orders for flow control equipment. The company has widened its range through acquisitions and sells to customers in India and overseas.

What to watch: Track order inflow from water projects and the margin trend as new product lines scale.

Glenmark Pharmaceuticals vs Rossari Biotech vs Jash Engineering on Key Financials

The table below sets the three pharma, specialty chemical and gate stocks side by side on revenue, profit and margin, using reported figures.

Glenmark Pharmaceuticals posts the highest return on equity in this group at 28.1%. Glenmark Pharmaceuticals has the largest FY26 revenue at Rs 17,443 crore, and Jash Engineering shows the fastest revenue growth with a 19.3% compound annual rate. A useful habit with pharma, specialty chemical and gate stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Pharma, Specialty Chemical and Gate Stocks

Every theme carries risks that deserve a check before any decision. For these pharma, specialty chemical and gate stocks, the main points are:

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Government spending. Public project funding can shift between periods.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter pharma, specialty chemical and gate stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Pharma, Specialty Chemical and Gate Stocks

Pharma, specialty chemical and gate stocks suit investors who prefer to study business strength before price moves. Glenmark Pharmaceuticals, Rossari Biotech and Jash Engineering each have a clear plan to grow. Based on the 3 November 2026 close, Glenmark Pharmaceuticals trades at Rs 2,408, Rossari Biotech at Rs 407.35 and Jash Engineering at Rs 484.15.

Download the Univest iOS App or Univest Android App to track pharma, specialty chemical and gate stocks, set price alerts and get research-backed stock ideas.

What are pharma, specialty chemical and gate stocks?

Ans. Pharma, specialty chemical and gate stocks are listed companies that make branded generics and speciality medicines, produce home care, textile and animal nutrition chemicals, and build sluice gates, valves and penstocks for water and wastewater projects. Their earnings depend on prescriptions, chemical demand and water project spending. This list looks at three of them, Glenmark Pharmaceuticals, Rossari Biotech and Jash Engineering, using reported FY22 to FY26 financials and the 3 November 2026 closing prices.

Which pharma, specialty chemical and gate stocks are covered in this list?

Ans. This list covers Glenmark Pharmaceuticals, Rossari Biotech and Jash Engineering. Based on the 3 November 2026 close, Glenmark Pharmaceuticals traded at Rs 2,408, Rossari Biotech at Rs 407.35 and Jash Engineering at Rs 484.15. Their return on equity ranges from 10.8% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 19.3%.

Why do pharma, specialty chemical and gate stocks have a strong future roadmap in India?

Ans. Pharma, specialty chemical and gate stocks have a strong roadmap in India because growing medicine use, wider specialty chemical applications and large water infrastructure plans keep widening the market for these companies. The main drivers are as follows. Pharma. Branded and speciality medicines reach more patients. Specialty chemicals. Home and textile makers need performance ingredients. Flow control. Water projects need gates and valves. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Glenmark Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7. Looking ahead, the company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.

How has Rossari Biotech performed financially?

Ans. Revenue rose from Rs 1,495 crore in FY22 to Rs 2,419 crore in FY26, a compound annual growth rate of 12.8%. Net profit grew from Rs 97.7 crore in FY22 to Rs 149 crore in FY26, which works out to a compound annual growth rate of 11.2%. The company has a return on equity of 10.8%, a debt to equity ratio of 0.28 and a market capitalisation of Rs 2,363 crore. The stock trades at a P/E of 15.5, below the industry P/E of 33.9. Looking ahead, the company is broadening its range across home and personal care, animal nutrition and performance chemicals. Cross-selling to existing customers helps add volume.

How has Jash Engineering performed financially?

Ans. Revenue rose from Rs 374 crore in FY22 to Rs 757 crore in FY26, a compound annual growth rate of 19.3%. Net profit grew from Rs 32.2 crore in FY22 to Rs 75.5 crore in FY26, which works out to a compound annual growth rate of 23.8%. In the June 2026 quarter, revenue grew 17.3% year on year to Rs 156 crore. The company has a return on equity of 14.7%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 3,380 crore. The stock trades at a P/E of 39.4, below the industry P/E of 44.4. Looking ahead, spending on water supply, sewage treatment and irrigation projects creates a steady stream of orders for flow control equipment. The company has widened its range through acquisitions and sells to customers in India and overseas.

What risks should investors check before buying pharma, specialty chemical and gate stocks?

Ans. Investors should check a few risks before buying pharma, specialty chemical and gate stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Government spending. Public project funding can shift between periods. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of pharma, specialty chemical and gate stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 3 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.